We see your Memorial Sloan Kettering, MD Anderson, Mayo Clinic, Johns Hopkins, and Dana Farber, and raise you "The Revolution Cancer International Molecular Tumor Board".  Come watch what actually happens outside the walls of academia, and prepare to be AMAZED. 

In this edition of the Revolution Cancer International Molecular Tumor Board, prepare to have your mind blown.  Learn about the incredible Daiichi Sankyo pipeline first-hand from Basem Goueli MD, Ph.D., MBA, and Janakiraman Subramanian MD.  Watch and listen as they provide you with the behind-the-scenes information you require, and educate you about a paradigm shift in breast cancer.  Dr. Goueli provides the listener with the best review of the low HER2 breast cancer space presently available.   In addition, Dr. Goueli and Dr. Subramanian talk about the likely upcoming trastuzumab duocarmazine approval, and review HER2, FGFR2, AKT, PIK3CA, HER3, and TROP2 inhibitors.  

If that isn't enough Dr. Goueli, Dr. Subrmanian, and Dr. Maskomani reveal the next evolution in molecular tumor boards.  They use the COMET algorithm in cancer patient treatment cartography to develop an ideal treatment map for a patient with Stage 4, ER+, PR+, low HER, breast cancer, with FIVE PIK3CA mutations, an AKT1 mutation, and an FGFR2 mutation.  During the presentation they provide the MOST COMPREHENSIVE REVIEW of the stage 4 hormone receptor positive, lowHER2 space you will find.  In addition, they  discuss elacestrant, which is currently being reviewed for FDA approval.

The Revolution Cancer International Molecular Tumor Board is unabashedly futuristic.  ou have never seen a tumor board like this. If you don't believe us, see for yourself.